﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2024v5.2">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2025-11-17T20:11:32-06:00</ReturnTs>
    <TaxPeriodEndDt>2024-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>331197384</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>ANDERSEN TAX LLC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>611 ANTON BOULEVARD STE 1200</AddressLine1Txt>
        <CityNm>COSTA MESA</CityNm>
        <StateAbbreviationCd>CA</StateAbbreviationCd>
        <ZIPCd>92626</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2024-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>880639274</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>INSTITUTE FOR FOLLICULAR LYMPHOMA</BusinessNameLine1Txt>
        <BusinessNameLine2Txt>INNOVATION</BusinessNameLine2Txt>
      </BusinessName>
      <BusinessNameControlTxt>INST</BusinessNameControlTxt>
      <PhoneNum>3102822353</PhoneNum>
      <USAddress>
        <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
        <CityNm>DIAMOND BAR</CityNm>
        <StateAbbreviationCd>CA</StateAbbreviationCd>
        <ZIPCd>91765</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>DAVID MCCULLAGH</PersonNm>
      <PersonTitleTxt>CFO</PersonTitleTxt>
      <PhoneNum>3102822353</PhoneNum>
      <SignatureDt>2025-11-17</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>0</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>KATHRYN M MATHIESON</PreparerPersonNm>
      <PTIN>P01696000</PTIN>
      <PhoneNum>9498854550</PhoneNum>
      <PreparationDt>2025-11-17</PreparationDt>
    </PreparerPersonGrp>
    <TaxYr>2024</TaxYr>
    <BuildTS>2025-03-06 01:10:19Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="12">
    <IRS990PF documentId="RetDoc1235000001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>26648601</FMVAssetsEOYAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AnalysisOfRevenueAndExpenses>
        <ContriRcvdRevAndExpnssAmt>20101612</ContriRcvdRevAndExpnssAmt>
        <DividendsRevAndExpnssAmt>562955</DividendsRevAndExpnssAmt>
        <DividendsNetInvstIncmAmt>569468</DividendsNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>-949</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>100668</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>86177</CapGainNetIncmNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>20663618</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>655645</TotalNetInvstIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>0</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>0</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>0</CompOfcrDirTrstDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">221043</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>0</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>192531</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">22800</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>11000</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>11800</AccountingFeesChrtblPrpsAmt>
        <OtherProfFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002300001">2875737</OtherProfFeesRevAndExpnssAmt>
        <OtherProfFeesNetInvstIncmAmt>0</OtherProfFeesNetInvstIncmAmt>
        <OtherProfFeesDsbrsChrtblAmt>2678616</OtherProfFeesDsbrsChrtblAmt>
        <TaxesRevAndExpnssAmt referenceDocumentId="RetDoc2002500001">7500</TaxesRevAndExpnssAmt>
        <TaxesNetInvstIncmAmt>0</TaxesNetInvstIncmAmt>
        <TaxesDsbrsChrtblAmt>8020</TaxesDsbrsChrtblAmt>
        <TravConfMeetingRevAndExpnssAmt>70496</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>0</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>58376</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">403663</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>0</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>14605</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>3601239</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>11000</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>2963948</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>4563256</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>9045427</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>8164495</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>11000</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>12009375</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>12499123</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>644645</NetInvestmentIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <CashBOYAmt>14881624</CashBOYAmt>
        <CashEOYAmt>14430485</CashEOYAmt>
        <CashEOYFMVAmt>12987703</CashEOYFMVAmt>
        <PrepaidExpensesEOYAmt>1000000</PrepaidExpensesEOYAmt>
        <PrepaidExpensesEOYFMVAmt>1000000</PrepaidExpensesEOYFMVAmt>
        <USGovernmentObligationsBOYAmt>1698494</USGovernmentObligationsBOYAmt>
        <USGovernmentObligationsEOYAmt>0</USGovernmentObligationsEOYAmt>
        <USGovtObligationsEOYFMVAmt>0</USGovtObligationsEOYFMVAmt>
        <LandBldgEquipCostOrOtherBssAmt>11048</LandBldgEquipCostOrOtherBssAmt>
        <LandBOYAmt>0</LandBOYAmt>
        <LandEOYAmt>11048</LandEOYAmt>
        <LandEOYFMVAmt>11048</LandEOYFMVAmt>
        <OtherAssetsBOYAmt referenceDocumentId="RetDoc2046600001">763698</OtherAssetsBOYAmt>
        <OtherAssetsEOYAmt referenceDocumentId="RetDoc2046600001">11207068</OtherAssetsEOYAmt>
        <OtherAssetsEOYFMVAmt referenceDocumentId="RetDoc2046600001">12649850</OtherAssetsEOYFMVAmt>
        <TotalAssetsBOYAmt>17343816</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>26648601</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>26648601</TotalAssetsEOYFMVAmt>
        <AccountsPayableBOYAmt>229067</AccountsPayableBOYAmt>
        <AccountsPayableEOYAmt>553822</AccountsPayableEOYAmt>
        <GrantsPayableBOYAmt>8114733</GrantsPayableBOYAmt>
        <GrantsPayableEOYAmt>4901644</GrantsPayableEOYAmt>
        <TotalLiabilitiesBOYAmt>8343800</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>5455466</TotalLiabilitiesEOYAmt>
        <OrgDoesNotFollowFASB117Ind>X</OrgDoesNotFollowFASB117Ind>
        <CapitalStockBOYAmt>0</CapitalStockBOYAmt>
        <CapitalStockEOYAmt>0</CapitalStockEOYAmt>
        <AdditionalPaidInCapitalBOYAmt>0</AdditionalPaidInCapitalBOYAmt>
        <AdditionalPaidInCapitalEOYAmt>0</AdditionalPaidInCapitalEOYAmt>
        <RetainedEarningBOYAmt>9000016</RetainedEarningBOYAmt>
        <RetainedEarningEOYAmt>21193135</RetainedEarningEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>9000016</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>21193135</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>17343816</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>26648601</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>9000016</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>12499123</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt>0</OtherIncreasesAmt>
        <SubtotalAmt>21499139</SubtotalAmt>
        <OtherDecreasesAmt referenceDocumentId="RetDoc2049800001">306004</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>21193135</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PUBLICLY TRADED SECURITIES</PropertyDesc>
          <HowAcquiredCd>D</HowAcquiredCd>
          <GrossSalesPriceAmt>100668</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>14491</CostOrOtherBasisAmt>
          <GainOrLossAmt>86177</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>86177</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>86177</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>8961</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>8961</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>8961</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>4751</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>176000</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>180751</TotalPaymentsAndCreditsAmt>
        <EsPenaltyAmt>0</EsPenaltyAmt>
        <OverpaymentAmt>171790</OverpaymentAmt>
        <AppliedToESTaxAmt>171790</AppliedToESTaxAmt>
        <RefundAmt>0</RefundAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>CA</OrgReportOrRegisterStateCd>
        <OrgReportOrRegisterStateCd>DE</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd referenceDocumentId="RetDoc2089200001">1</NewSubstantialContributorsInd>
        <OwnControlledEntityInd>0</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>N/A</WebsiteAddressTxt>
        <IndividualWithBooksNm>DAVID MCCULLAGH</IndividualWithBooksNm>
        <PhoneNum>9497422213</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
          <CityNm>DIAMOND BAR</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91765</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>0</ForeignAccountsQuestionInd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>0</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>0</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>1</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>0</BusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>1</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <TransactionsFailToQlfyAsExcInd>0</TransactionsFailToQlfyAsExcInd>
        <MaintainedExpenditureRspnsInd referenceDocumentId="RetDoc2118100001">1</MaintainedExpenditureRspnsInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ANDREW PEYKOFF II</PersonNm>
          <USAddress>
            <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
            <CityNm>DIAMOND BAR</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91765</ZIPCd>
          </USAddress>
          <TitleTxt>PRESIDENT/DIRECTOR</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>0.50</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>KENT RATZLAFF</PersonNm>
          <USAddress>
            <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
            <CityNm>DIAMOND BAR</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91765</ZIPCd>
          </USAddress>
          <TitleTxt>SECRETARY/DIRECTOR</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>0.10</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>DAVID MCCULLAGH</PersonNm>
          <USAddress>
            <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
            <CityNm>DIAMOND BAR</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91765</ZIPCd>
          </USAddress>
          <TitleTxt>CFO/DIRECTOR</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>10.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompOfHghstPdEmplOrNONETxt>NONE</CompOfHghstPdEmplOrNONETxt>
        <OtherEmployeePaidOver50kCnt>0</OtherEmployeePaidOver50kCnt>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>WTRSHD CAPITAL LLC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>2700 E SUNSET RD SUITE 16</AddressLine1Txt>
            <CityNm>LAS VEGAS</CityNm>
            <StateAbbreviationCd>NV</StateAbbreviationCd>
            <ZIPCd>89120</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>PROFESSIONAL SERVICES</ServiceTypeTxt>
          <CompensationAmt>1279618</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>TEMPUS AI INC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>600 WEST CHICAGO AVE SUITE 510</AddressLine1Txt>
            <CityNm>CHICAGO</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60654</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>PROFESSIONAL SERVICES</ServiceTypeTxt>
          <CompensationAmt>500000</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>NOVOCREATION CONSULTING LLC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>978 BAILEYS CHAPEL ROAD</AddressLine1Txt>
            <CityNm>ADVANCE</CityNm>
            <StateAbbreviationCd>NC</StateAbbreviationCd>
            <ZIPCd>270067146</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>PROFESSIONAL SERVICES</ServiceTypeTxt>
          <CompensationAmt>239580</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>OPUS 12 LLC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>2307 BONAR ST</AddressLine1Txt>
            <CityNm>BERKELEY</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>94702</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>PROFESSIONAL SERVICES</ServiceTypeTxt>
          <CompensationAmt>235367</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>LUMANITY ASSET AND ORGANIZATIONAL STRATEGY LLC</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>280 SUMMER STREET 8TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02210</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>PROFESSIONAL SERVICES</ServiceTypeTxt>
          <CompensationAmt>191963</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <ContractorPaidOver50kCnt>3</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SumOfProgramRelatedInvstGrp>
        <Description1Txt>PEPROMENE BIO, INC.THE PURPOSE OF THIS PROGRAM-RELATED INVESTMENT (PRI) IS TO SUPPORT THE EXPANSION OF A PHASE 1 CLINICAL TRIAL EVALUATING PEPROMENE'S BAFFRTARGETING CAR T-CELL THERAPY (PMB-102) TO INCLUDE FOLLICULAR LYMPHOMA PATIENTS. THE FUNDING ENABLES ASSESSMENT OF SAFETY, DOSE, AND EARLY CLINICAL ACTIVITY IN THIS COHORT AND ALIGNS WITH IFLI'S MISSION TO ACCELERATE DEVELOPMENT OF INNOVATIVE TREATMENTS FOR INDOLENT LYMPHOMAS.</Description1Txt>
        <Expenses1Amt>6000005</Expenses1Amt>
        <Description2Txt>INNATE PHARMATHE PURPOSE OF THIS PROGRAM-RELATED INVESTMENT (PRI) IS TO SUPPORT INNATE PHARMA'S DEVELOPMENT OF NOVEL IMMUNOTHERAPIES FOR FOLLICULAR LYMPHOMA, ENABLING ADVANCEMENTTHROUGH PRECLINICAL AND EARLY CLINICAL STAGES. THE INVESTMENT ALIGNS WITH IFLI'S MISSION TO ACCELERATE INNOVATION IN INDOLENT LYMPHOMAS BY BACKING COMPANIES DEVELOPING TRANSFORMATIVE TREATMENTS.</Description2Txt>
        <Expenses2Amt>3000001</Expenses2Amt>
        <AllOtherProgramRltdInvstTotAmt referenceDocumentId="RetDoc2063500001">1769879</AllOtherProgramRltdInvstTotAmt>
        <TotalAmt>10769885</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>10106854</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>1426055</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>0</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>11532909</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>11532909</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>172994</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>11359915</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>567996</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>567996</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>8961</TaxBasedOnInvestmentIncomeAmt>
        <TotalTaxAmt>8961</TotalTaxAmt>
        <DistributableBeforeAdjAmt>559035</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>0</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>559035</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>559035</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>12009375</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>10769885</ProgramRelatedInvstTotalAmt>
        <QualifyingDistributionsAmt>22779260</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>559035</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>0</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <ExcessDistributionCyovYr2Amt>3851207</ExcessDistributionCyovYr2Amt>
        <ExcessDistributionCyovYr1Amt>6004325</ExcessDistributionCyovYr1Amt>
        <TotalExcessDistributionCyovAmt>9855532</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>22779260</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>0</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>559035</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>22220225</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>32075757</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>0</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>32075757</ExcessDistriCyovToNextYrAmt>
        <ExcessFromYear2Amt>3851207</ExcessFromYear2Amt>
        <ExcessFromYear1Amt>6004325</ExcessFromYear1Amt>
        <ExcessFromCurrentYearAmt>22220225</ExcessFromCurrentYearAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <OnlyContriToPreselectedInd>X</OnlyContriToPreselectedInd>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BECKMAN RESEARCH INSTITUTE - CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 EAST DUARTE ROAD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>467783</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSERM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 RUE TOLBIAC</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <ProvinceOrStateNm>PARIS CEDEX 13</ProvinceOrStateNm>
            <CountryCd>FR</CountryCd>
            <ForeignPostalCd>75654</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>239133</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LYMPHOMA RESEARCH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 PINE ST SUITE 2400</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10005</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>3282650</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LYSARC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CENTRE HOSPITALIER LYON SUD</AddressLine1Txt>
            <CityNm>PIERRE BENITE</CityNm>
            <CountryCd>FR</CountryCd>
            <ForeignPostalCd>69495</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>2336450</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE FRANCIS CRICK INSTITUTE LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 MIDLAND ROAD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>NW1 1AT</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>249969</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LEUKEMIA &amp; LYMPHOMA SOCIETY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 INTERNATIONAL DRIVE SUITE 200</AddressLine1Txt>
            <CityNm>RYE BROOK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>1211957</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UCLA</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10833 LE CONTE AVE</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90095</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>275000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>MSC 1054-0087-01 ONE BROOKINGS</AddressLine1Txt>
            <AddressLine2Txt>DRIVE</AddressLine2Txt>
            <CityNm>ST LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63130</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>700960</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CURE (LLSFLFIFLI)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 INTERNATIONAL DRIVE SUITE 200</AddressLine1Txt>
            <CityNm>RYE BROOK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>223667</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RAFL PROGRAM (IFLI &amp; LLS COLLABORATION)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 INTERNATIONAL DRIVE SUITE 200</AddressLine1Txt>
            <CityNm>RYE BROOK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>57858</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>9045427</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BECKMAN RESEARCH INSTITUTE - CITY OF HOPE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1500 EAST DUARTE ROAD</AddressLine1Txt>
            <CityNm>DUARTE</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91010</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>1151166</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSERM</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>101 RUE TOLBIAC</AddressLine1Txt>
            <CityNm>PARIS</CityNm>
            <ProvinceOrStateNm>PARIS CEDEX 13</ProvinceOrStateNm>
            <CountryCd>FR</CountryCd>
            <ForeignPostalCd>75654</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>311117</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LYSARC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>CENTRE HOSPITALIER LYON SUD</AddressLine1Txt>
            <CityNm>PIERRE BENITE</CityNm>
            <CountryCd>FR</CountryCd>
            <ForeignPostalCd>69495</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>2034383</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE FRANCIS CRICK INSTITUTE LIMITED</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>1 MIDLAND ROAD</AddressLine1Txt>
            <CityNm>LONDON</CityNm>
            <CountryCd>UK</CountryCd>
            <ForeignPostalCd>NW1 1AT</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>NC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>199975</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE LEUKEMIA &amp; LYMPHOMA SOCIETY INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 INTERNATIONAL DRIVE SUITE 200</AddressLine1Txt>
            <CityNm>RYE BROOK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>250000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WASHINGTON UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>MSC 1054-0087-01 ONE BROOKINGS</AddressLine1Txt>
            <AddressLine2Txt>DRIVE</AddressLine2Txt>
            <CityNm>ST LOUIS</CityNm>
            <StateAbbreviationCd>MO</StateAbbreviationCd>
            <ZIPCd>63130</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>700961</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>LYMPHOMA RESEARCH FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>88 PINE ST SUITE 2400</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10005</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>284350</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CURE (LLSFLFIFLI)</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3 INTERNATIONAL DRIVE SUITE 200</AddressLine1Txt>
            <CityNm>RYE BROOK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10573</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA</GrantOrContributionPurposeTxt>
          <Amt>447333</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>5379285</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <DividendsAndInterestFromSecDtl>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>562955</ExclusionAmt>
        </DividendsAndInterestFromSecDtl>
        <GainSalesAstOthThanInvntryGrp>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>-949</ExclusionAmt>
        </GainSalesAstOthThanInvntryGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>0</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>562006</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>0</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>562006</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>0</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <GeneralRuleInd>X</GeneralRuleInd>
      <ContributorInformationGrp>
        <ContributorNum>1</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1Txt>NIAGARA BOTTLING LLC</BusinessNameLine1Txt>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
          <CityNm>DIAMOND BAR</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91765</ZIPCd>
        </ContributorUSAddress>
        <TotalContributionsAmt>20000000</TotalContributionsAmt>
        <PersonContributionInd>X</PersonContributionInd>
      </ContributorInformationGrp>
      <ContributorInformationGrp>
        <ContributorNum>2</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1Txt>DAVID &amp; ELIZABETH MCCULLAGH</BusinessNameLine1Txt>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1Txt>1727 PORT BARMOUTH PL</AddressLine1Txt>
          <CityNm>NEWPORT BEACH</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92660</ZIPCd>
        </ContributorUSAddress>
        <TotalContributionsAmt>101618</TotalContributionsAmt>
        <NoncashContributionInd>X</NoncashContributionInd>
      </ContributorInformationGrp>
      <NonCashPropertyContributionGrp>
        <ContributorNum>2</ContributorNum>
        <NoncashPropertyDesc>71 APPLE SHARES, $253.48 EACH, TOTAL $17,997. 184 MICROSOFT SHARES, $454.46 EACH, TOTAL $83,621.</NoncashPropertyDesc>
        <FairMarketValueAmt>101618</FairMarketValueAmt>
        <ReceivedDt>2024-12-17</ReceivedDt>
      </NonCashPropertyContributionGrp>
    </IRS990ScheduleB>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>ACCOUNTING FEES</CategoryTxt>
        <Amt>22800</Amt>
        <NetInvestmentIncomeAmt>11000</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>11800</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <AllOthProgRltdInvestmentsSch documentId="RetDoc2063500001">
      <AllOtherProgramRelatedInvstGrp>
        <Desc>ARARIS BIOTECH LTD THE PURPOSE OF THIS PROGRAM-RELATED INVESTMENT (PRI) IS TO ADVANCE THE DEVELOPMENT OF A BREAKTHROUGH TECHNOLOGY PLATFORM BY ARARIS BIOTECH LTD, AIMED AT CREATING INNOVATIVE DRUG TREATMENTS FOR FOLLICULAR LYMPHOMA AND OTHER INDOLENT LYMPHOMAS.</Desc>
        <Amt>969879</Amt>
      </AllOtherProgramRelatedInvstGrp>
      <AllOtherProgramRelatedInvstGrp>
        <Desc>VERISMO THERAPEUTICS, INC. THE PURPOSE OF THIS PROGRAM-RELATED INVESTMENT (PRI) IS TO SUPPORT VERISMO THERAPEUTICS' PHASE 1 CLINICAL TRIAL OF ITS SYNKIR-310 THERAPY BY EXPANDING ENROLLMENT OF FOLLICULAR LYMPHOMA PATIENTS.</Desc>
        <Amt>800000</Amt>
      </AllOtherProgramRelatedInvstGrp>
    </AllOthProgRltdInvestmentsSch>
    <ExpenditureResponsibilityStmt documentId="RetDoc2118100001">
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>LYSARC</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>CENTRE HOSPITALIER</AddressLine1Txt>
          <CityNm>PIERREBENITE</CityNm>
          <CountryCd>FR</CountryCd>
          <ForeignPostalCd>69495</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2023-09-27</GrantDt>
        <GrantAmt>5932761</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3968991</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>07/01/24</DatesOfReportsByGranteeTxt>
        <VerificationDt>2024-07-01</VerificationDt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ARARIS BIOTECH LTD</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>RIEDHOFSTRASSE 11</AddressLine1Txt>
          <CityNm>ZURICH</CityNm>
          <CountryCd>SZ</CountryCd>
          <ForeignPostalCd>CH-8804</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2022-09-02</GrantDt>
        <GrantAmt>1888676</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>1733577</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>09/06/24</DatesOfReportsByGranteeTxt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INNATE PHARMA</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>117 AVENUE DE LUMINY</AddressLine1Txt>
          <CityNm>MARSEILLE</CityNm>
          <CountryCd>FR</CountryCd>
          <ForeignPostalCd>13009</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2024-12-05</GrantDt>
        <GrantAmt>3320289</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>3000001</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THE FRANCIS CRICK INSTITUTE LIMITED</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>1 MIDLAND ROAD</AddressLine1Txt>
          <CityNm>LONDON</CityNm>
          <CountryCd>UK</CountryCd>
          <ForeignPostalCd>NW1 1AT</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2024-04-01</GrantDt>
        <GrantAmt>499938</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>249969</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INSERM</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>101 RUE TOLBIAC</AddressLine1Txt>
          <CityNm>PARIS</CityNm>
          <ProvinceOrStateNm>PARIS CEDEX 13</ProvinceOrStateNm>
          <CountryCd>FR</CountryCd>
          <ForeignPostalCd>75654</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2024-08-01</GrantDt>
        <GrantAmt>550250</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>239133</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PEPROMENE BIO INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>15375 BARRANCA PARKWAY A-211</AddressLine1Txt>
          <CityNm>IRVINE</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92618</ZIPCd>
        </USAddress>
        <GrantDt>2024-12-18</GrantDt>
        <GrantAmt>11000045</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>6000005</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>VERISMO THERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>3675 MARKET STREET SUITE 200</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19104</ZIPCd>
        </USAddress>
        <GrantDt>2024-12-30</GrantDt>
        <GrantAmt>4050000</GrantAmt>
        <PurposeOfGrantTxt>FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>800000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>TO THE KNOWLEDGE OF THE FOUNDATION, NO FUNDS HAVE BEEN DIVERTED.</AnyDiversionByGranteeTxt>
        <ResultsOfVerificationTxt>THE FOUNDATION REVIEWED ANY GRANT REPORTS RECEIVED UPON RECEIPT. THERE HAS NOT BEEN ANY REASON TO DOUBT THEIR ACCURACY OR RELIABILITY REQUIRING THE FOUNDATION TO UNDERTAKE ANY VERIFICATION OF THE GRANTEE'S REPORTS.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
    </ExpenditureResponsibilityStmt>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES</CategoryTxt>
        <LegalFeesAmt>221043</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>192531</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherAssetsSchedule documentId="RetDoc2046600001">
      <OtherAssetsScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENTS</Desc>
        <BOYBookValueAmt>763698</BOYBookValueAmt>
        <EOYBookValueAmt>11207068</EOYBookValueAmt>
        <EOYFMVAmt>12649850</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
    </OtherAssetsSchedule>
    <OtherDecreasesSchedule documentId="RetDoc2049800001">
      <OtherDecreasesDetail>
        <Desc>UNREALIZED GAIN/LOSS ON INVESTMENTS</Desc>
        <Amt>306004</Amt>
      </OtherDecreasesDetail>
    </OtherDecreasesSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>BUSINESS LICENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>545</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>POSTAGE</Desc>
        <RevenueAndExpensesPerBooksAmt>30</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>COMPUTER SOFTWARE</Desc>
        <RevenueAndExpensesPerBooksAmt>2087</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>2087</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>BANK CHARGES</Desc>
        <RevenueAndExpensesPerBooksAmt>1714</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1186</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>OFFICE SUPPLIES</Desc>
        <RevenueAndExpensesPerBooksAmt>943</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>943</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>DUES AND SUBSCRIPTIONS</Desc>
        <RevenueAndExpensesPerBooksAmt>22496</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>ADVERTISING</Desc>
        <RevenueAndExpensesPerBooksAmt>12690</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>PROGRAM - NETWORKING EVENTS</Desc>
        <RevenueAndExpensesPerBooksAmt>34341</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>BIOTECH SERVICES AND DUE DILIGENCE</Desc>
        <RevenueAndExpensesPerBooksAmt>112974</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>10389</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>AMORTIZATION OF DISCOUNT OF GRANTS PAYABLE</Desc>
        <RevenueAndExpensesPerBooksAmt>215843</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherProfessionalFeesSchedule documentId="RetDoc2002300001">
      <OtherProfessionalFeesDetail>
        <CategoryTxt>CONSULTING FEES</CategoryTxt>
        <Amt>742842</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>744782</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>IFLI FULL AND PART TIME TEAM CONSULTING FEES</CategoryTxt>
        <Amt>1876892</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>1811144</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>AUDIT FEES</CategoryTxt>
        <Amt>49230</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>IFLI FULL AND PART TIME TEAM RECRUITING FEES</CategoryTxt>
        <Amt>200000</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>122690</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>IFLI FULL AND PART TIME TEAM REIMBURSEMENT</CategoryTxt>
        <Amt>6773</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
    </OtherProfessionalFeesSchedule>
    <SubstantialContributorsSch documentId="RetDoc2089200001">
      <SubstantialContributorDetail>
        <BusinessName>
          <BusinessNameLine1Txt>NIAGARA BOTTLING LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1440 BRIDGEGATE DRIVE</AddressLine1Txt>
          <CityNm>DIAMOND BAR</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>91765</ZIPCd>
        </USAddress>
      </SubstantialContributorDetail>
      <SubstantialContributorDetail>
        <PersonNm>DAVID ELIZABETH MCCULLAGH</PersonNm>
        <USAddress>
          <AddressLine1Txt>1727 PORT BARMOUTH PL</AddressLine1Txt>
          <CityNm>NEWPORT BEACH</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92660</ZIPCd>
        </USAddress>
      </SubstantialContributorDetail>
    </SubstantialContributorsSch>
    <TaxesSchedule documentId="RetDoc2002500001">
      <TaxesDetail>
        <CategoryTxt>FEDERAL TAX</CategoryTxt>
        <Amt>7500</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>8020</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
    </TaxesSchedule>
  </ReturnData>
</Return>